[{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Treprostinil Diolamine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : UT-15C is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 17, 2014

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 04, 2013

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : UT-15C is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 11, 2012

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 01, 2012

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 22, 2012

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 22, 2012

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 22, 2011

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diethanolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 29, 2010

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diethanolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 19, 2010

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Treprostinil Diethanolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 30, 2010

                          Lead Product(s) : Treprostinil Diolamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank